POST LEONARD E sold $71K of CGON
POST LEONARD E sold 1,000 shares of CG Oncology, Inc. (CGON) at $71.17 on 2026-07-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale of 1,000 shares at $71.17 under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure and modest dollar value reduce expected price impact.
What to watch
Director role and post-sale holdings drop to zero, but without additional context (other sales, options exercises, or material events) it is not a strong fundamental catalyst.
Background
The article is an SEC Form 4 insider transaction disclosure for CG Oncology, Inc.
Ticker impact
SEC Form 4 shows director POST LEONARD E sold 1,000 CG Oncology shares on 2026-07-15 at $71.17, leaving 0 shares.
Likely minimal near-term impact; any effect would be sentiment-only and typically fades.
The filing is a Form 4 insider sale, but it is explicitly under a pre-arranged Rule 10b5-1 plan and the transaction size is small ($71.17k).
Market effects
No clear sector read-through from a single small 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can be purely mechanical (tax planning or diversification) and may not reflect bearish expectations.
Key entities
- issuerCG Oncology, Inc.
Company whose Form 4 insider sale is disclosed.
- insiderPOST LEONARD E
Director who sold 1,000 shares under a Rule 10b5-1 plan.